Bévacizumab (biosimilaire) dans le traitement du CCRM et du CPNPC

Détails

Generic Name:
Bévacizumab
État du projet:
Annulé
Fabricant:
Pfizer Canada
Brand Name:
À déterminer
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0178-000
Tumour Type:
Gastrointestinal/Poumon
Indications:
Cancer colorectal métastatique; cancer du poumon non à petites cellules
Funding Request:
Cancer colorectal métastatique (CCRM); cancer du poumon non à petites cellules (CPNPC)
Review Status:
Cancelled
Pre Noc Submission:
Yes
Sponsor:
Pfizer Canada
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.